Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Nature Medicine explores the latest translation and clinical research news, with results from a phase 2 clinical trial of zilebesiran from Alnylam and Roche.
Alnylam and Roche have announced that their investigational RNA interference drug that targets angiotensinogen reduced patients’ mean systolic blood pressure. Patients in the zilebesiran arms of the KARDIA-1 trial saw reductions in systolic blood pressure of more than 15 mmHg at 3 months after administration and continued to show a sustained reduction up to 6 months after subcutaneous administration of the drug, which met the primary endpoint of the phase 2 trial. The randomized placebo-controlled trial enrolled 394 adults with mild to moderate hypertension (135–60 mmHg). Details on the adverse effects of the treatment are not yet available, with the press release noting an “encouraging safety and tolerability profile.”